Meeting
2020 ASCO Virtual Scientific Program
CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Authors
David S. Hong
MD Anderson Cancer Center, Houston, TX
David S. Hong , James Kuo , Adrian G. Sacher , Fabrice Barlesi , Benjamin Besse , Yasutoshi Kuboki , Grace K. Dy , Vikas Dembla , John C. Krauss , Timothy F. Burns , June Kim , Haby Henary , Gataree Ngarmchamnanrith , Bob T. Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03600883
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3511)
DOI
10.1200/JCO.2020.38.15_suppl.3511
Abstract #
3511
Poster Bd #
241
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
First Author: Qing Zhou
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
First Author: Marwan Fakih
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Susanna Varkey Ulahannan